This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.

The drug and biotech sector has recovered somewhat in 2026 after remaining muted for most of 2025. Drug pricing agreements of ...

The current reality is one of verified, world-class innovation that positions Uganda as a hub for advanced biotechnology ...

BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. Click to read why BNTX is a Buy.

Following a difficult start in 2025, the ever-evolving life sciences segment recovered strongly in the latter half of the year.

Moderna, Inc. (NASDAQ: MRNA) shares are swinging in volatile early trading on Friday, February 27, 2026, as investors digest ...

Buy-rated picks in these sectors include Amgen ( AMGN ), Gilead Sciences ( GILD ), Moderna ( MRNA ), and United Therapeutics ( UTHR) for biotech, and Alcoa ( AA ), Freeport-McMoRan ( FCX ), MP ...

Alnylam Canada ULC is pleased to announce it has received a positive recommendation from Canada's Drug Agency (CDA) for the public reimbursement of its RNAi therapeutic, AMVUTTRA®.1 In December 2025, ...

The company has had its ups -- the approval of its respiratory syncytial virus (RSV) vaccine back in 2024 -- and its downs -- the failure of its cytomegalovirus (CMV) vaccine candidate in a phase 3 ...

Phillip Frost, Chairman and Chief Executive Officer, will provide opening remarks. Elias Zerhouni, Vice Chairman and ...

Nexcom APPC 160/210 C21 panel PCs Unleashing the Ingenuity of SD Edge Computing with AIoT and AI Computing products New ...

ORLANDO, FL / ACCESS Newswire / February 9, 2026 / RedChip Companies, an industry leader in investor relations, media, ...